Reprogramming Myeloid Cells Enhances the Power of T-Cell Immunotherapy
Researchers have discovered that targeting PD-L1 recycling in myeloid cells enhances T-cell activation and boosts the effects of checkpoint blockade therapies.
A new antibody, H1A, shows promise for improving treatment outcomes.
We use cookies to provide you with a better experience.
Research Findings
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer.
Two research teams found that "first-responder" immune cells known as myeloid cells can be manipulated to enhance the activity of tumor-killing T cells.
The finding suggests that enhanced myeloid cells may boost certain immune checkpoint therapies, which are the standard of care for some cancers but may not have lasting effects.
No direct quote available in the text.
Author's summary: Researchers enhance T-cell immunotherapy by reprogramming myeloid cells.
More News
- Material Memory: What We Lose When We Demolish Buildings
- The River: Recent call revives memory of ill-fated steamer ALICE DEAN, sunk by Confederate raiders - NKyTribune
- Steve García demolishes a lifeless David Onama with a first-round finish at UFC Vegas 110
- techUK’s Autumn 2025 Budget submission
- Creators Are Ditching Google For Substack – Here’s Why…
- Operation Christmas Child: Time to Reconsider - THE OTHER CHEEK
- Ogden’s homeless plan: Less affordable housing, more rent-a-cops - The Utah Investigative Journalism Project
- Dodgers Cement Dynasty with Back-to-Back World Series Wins
- “The Cell and the Soul: A Prison Memoir” by Anand Teltumbde stands as one of the most powerful indictments of Indian democracy | SabrangIndia
- Anand Teltumbde on the caste census and his prison memoir